The Obesity Drug Race: From Breakthrough Science to Global Scale
The Life Science Effect
In this solo episode, Steve Vinson explores the rapidly evolving obesity drug market, highlighting insights from a recent Fierce Biotech power rankings article. He breaks down why Lilly and Novo Nordisk currently dominate, while examining the growing competitive field and what may determine the next wave of winners. The discussion focuses on the shift from breakthrough science to scalable execution and commercialization. Episode Overview The obesity drug market has transformed dramatically over the past decade, driven by the success of GLP-1 therapies like Ozempic, Wegovy, and Zepbound. In...
info_outline
Global Biopharma Manufacturing: Beyond Tariffs and Toward Resilience
The Life Science Effect
In this episode, Steve Vinson examines the sustained wave of biopharma manufacturing investment in North America and challenges the idea that tariffs were the primary driver. He explores the deeper forces reshaping the industry, including supply chain resilience, demand for complex biologics, and global uncertainty. The discussion focuses on what is actually being built, why it matters, and what to expect over the next one to three years. Episode Overview Steve Vinson steps back to assess the current state of global biopharma manufacturing, with a practical focus on North America. While...
info_outline
Why Prescription Drug Pricing Feels Broken: Cost, Complexity, and Trust in the U.S. System
The Life Science Effect
In this solo episode, Steve Vinson explores the confusing and often frustrating reality of prescription drug pricing in the United States. Through a personal story, he unpacks how the same medication can cost dramatically different amounts depending on how and where it is accessed. The episode highlights a deeper issue beyond cost—lack of transparency—and what that means for trust in the healthcare system. Episode Overview This episode starts with a real-world example that many listeners can relate to: discovering that the exact same prescription can vary widely in price across pharmacies,...
info_outline
Infrastructure as Innovation: How Ossium Health is Redefining Bone Marrow Access
The Life Science Effect
In this episode, Steve Vinson reflects on a recent Indianapolis Business Journal article about Ossium Health and its approach to bone marrow banking. He explores how innovation in life sciences often comes not from new discoveries, but from improving systems, logistics, and execution. The discussion highlights why infrastructure and operational excellence are becoming critical to the future of medicine—and why Indiana is uniquely positioned to lead. Episode Overview This episode examines Ossium Health’s effort to build a scalable bone marrow banking system using donations from deceased...
info_outline
AI Validating AI: The Future of Compliance in Life Sciences
The Life Science Effect
Artificial intelligence is moving fast—but in regulated life science environments, speed without trust is a non‑starter. In this episode of The Life Science Effect, host Steven Vinson reacts to a recent EY article on AI validation in pharmaceutical and biotech settings and explores a fascinating question: Can AI actually be used to validate other AI systems? Steven walks through how regulators are beginning to rethink traditional validation models to accommodate AI’s non‑deterministic nature, where the same input can produce different, but still acceptable, outputs. Drawing parallels...
info_outline
How Modular Biotech is Changing Everything - Even in Orbit
The Life Science Effect
In this episode, host Steve Vinson dives into one of the most futuristic — yet rapidly emerging — trends in life sciences: transportable and point‑of‑care pharmaceutical manufacturing. After discovering a compelling ISPE article, Steve explores how modular clean rooms, distributed manufacturing models, and space‑ready production units are reshaping the future of medicine. From personalized tablet production to on‑demand therapies in extreme environments, these technologies could redefine how and where healthcare happens. Drawing on his 30+ years in manufacturing, Steve connects...
info_outline
Global Biotech - Is America Falling Behind?
The Life Science Effect
In this episode, Steve Vinson dives into a provocative article by US Senator Todd Young, exploring the shifting landscape of global biotech innovation. With China’s rapid advances—highlighted by a breakthrough lung cancer drug—Steve analyzes the factors behind America’s waning leadership, from fragmented policy and regulatory uncertainty to funding challenges and talent migration. Drawing on his own industry experience, Steve discusses the impact of immigration crackdowns, supply chain vulnerabilities, and the long-term effects of reshoring manufacturing. Listeners will gain insight...
info_outline
Pharma 4.0: AI, Validation, and the Future of Life Sciences
The Life Science Effect
Step into the future of pharmaceutical and medical device innovation with Steve on The Life Science Effect. In this episode, Steve explores the transformative power of Pharma 4.0 and Validation 4.0, drawing insights from two thought-provoking blog posts by Robert Perks of Performance Validation. Discover how digital-first strategies, artificial intelligence, and continuous monitoring are reshaping compliance, quality assurance, and operational efficiency in life sciences. Steve breaks down the shift from paper-based systems to predictive analytics, highlighting the importance of aligning...
info_outline
The End of Solo Leadership: How Industry 4.0 is Changing the Game
The Life Science Effect
In this thought-provoking Active Ingredient episode, host Steve Vinson tackles a leadership paradigm that's challenging everything he thought he knew about accountability. Inspired by on breaking people silos, Steve dives deep into the tension between traditional "one person accountable" thinking and the emerging concept of shared accountability across teams. Drawing from his real-world experience designing process lane diagrams that keep spanning across departments, Steve explores why Industry 4.0 might be demanding a complete rethink of how we structure organizations. He examines the...
info_outline
Raul Zavaleta's Journey from UCLA to Life Science Legend
The Life Science Effect
Meet Raul Zavaleta, the visionary engineer whose innovations fundamentally transformed how clinical trials collect and process data. In this captivating conversation, Raul shares the incredible journey from UCLA graduate to co-founder of what became Covance - one of the world's largest clinical research organizations. Discover how a simple frustration with keypunch cards led to revolutionary solutions that reduced clinical trial data error rates from 39% to under 2% and compressed data cleaning timelines from six months to 48 hours. Raul reveals the story behind the Zavacor system, the...
info_outline16 Tech is the future of collaboration in downtown Indianapolis. It will bring together the talent, capital, and technology to make innovation happen.
Robert Coy is President and CEO of 16 Tech Community Corporation Inc., the entity overseeing the development of the 16 Tech innovation community. As President, Coy leads the development of 16 Tech into a major hub for scientific research, technology innovation, entrepreneurial activity and talent development, retention and attraction.
Prior to 16 Tech, Coy was President and CEO of CincyTech, a venture development organization that accelerated the growth of start-up bioscience, healthcare, technology and advanced manufacturing companies in Southwest Ohio. Under Coy’s leadership for more than 11 years, CincyTech invested in 70 startups that raised more than $680 million in seed, early and late stage capital and that today employ nearly 1,000 people.
Coy has held entrepreneurial and economic development leadership positions with public and private institutions over the past 32 years in Ohio, Missouri, Delaware and Pennsylvania.
Prior to joining CincyTech, Coy was senior vice president for entrepreneurial development and of economic development at the St. Louis Regional Chamber and Growth Association, where he co-founded the St. Louis Arch Angels, a group of individuals who invest in early-stage companies in the St. Louis region.
In Delaware, Coy served as the principal economic adviser to the governor, established a seed fund to invest in technology start-up companies and developed initiatives to promote technology partnerships between universities and businesses. In Pennsylvania, he served as executive director of the Ben Franklin Partnership Program, the state’s premier technology development program that invests in start-up companies.
Coy earned a master’s degree from University of Notre Dame and a bachelor of arts degree from Pennsylvania State University.